The purpose of this trial is to compare the pharmacokinetic characteristics of YHD1119 A, YHD1119 B, YHD1119 C and Lyrica capsule.

YHD1119 A, B, C are controlled released formulations which are made by YUHAN Corporation.

Primary endpoints are C max,ss and AUC tau. Secondary endpoints are AUC last, AUC infinity, T max,ss, t 1/2

Inclusion Criteria:

• 20~45 years old, healthy adult male subject
• >55 Kg(Body weight) and < ideal body weight ± 20%

Exclusion Criteria:

• AST or ALT > 1.25 * Upper normal range (Lab)
• Total bilirubin > 1.5 * Upper normal range
• Systolic BP >140 OR <100, Diastolic BP >90 OR <65